Replimune (REPL): Company Future Sales Volume

Future sales volume on the GURU.Markets platform reflects market expectations, where the 0.00 level represents the current value. Currently, Replimune Group, Inc. (REPL) generates revenue through partnerships as it prepares to launch its own oncolytics. The RPux technology will provide the company with pricing power due to its unique tumor-fighting mechanism, addressing massive latent demand within the immuno-oncology sector.

Company Revenue Forecast: Replimune Group, Inc. (REPL) for 07/04/2022 - 11/13/2026

REPL (Replimune Group Inc): analytical breakdowns and indicator data

- stock value and consensus price forecast:

Price Chart Replimune Group, Inc.|REPL - Consensus Target

- stock exchange capitalization data:

Market Valuation Replimune Group Inc|REPL - Enterprise Value

- issuer book value statistics:

Net Assets per Single Share Replimune|REPL - Accounting Capitalization|Market Value to Book Value Ratio replimune.com|REPL - Company Assets

- company liabilities and liquidity data:

- company profitability and valuation multiples indicators:

REPL - Final Profit|Projected Future Earnings Replimune Group, Inc.|REPL - P/E Multiple|Future Price to Earnings Replimune|REPL - Market Cap to Earnings and Growth Ratio|Enterprise Value to EBITDA Ratio Replimune Group Inc|REPL - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Replimune|REPL - Earnings per share for the trailing year|Quarterly EPS earnings growth replimune.com|REPL - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Replimune Group, Inc.

- sales revenue and business income indicators:

REPL - Company Annual Revenue|Company Projected Revenue Replimune Group, Inc.|REPL - Price-to-Revenue Ratio|Forward P/S Multiple Replimune Group Inc

Summary company analysis:Replimune Group, Inc.

This indicator measures projected revenue by analyzing market demand and price equilibria, allowing for an assessment of the fundamental potential of Replimune Group, Inc. (REPL) considering stringent FDA requirements and clinical trial costs. The current value of 0.00 within the company's sales volume projection signals the resilience of the business model to regulatory risks, helping investors identify asset value anomalies in a timely manner.

Direct competitors

Company Projected Revenue ImmunityBio, Inc. (IBRX)|Company Future Sales Volume immunocore.com IMCR|Janux Therapeutics, Inc. - Company Future Sales Volume|Projected Sales Volume Arcus Biosciences Inc RCUS|ZYME - Company Projected Revenue|TNGX (Tango Therapeutics Corp) - Company Revenue Forecast|Iovance Biotherapeutics (IOVA) - Company Projected Revenue|Company Expected Sales Volume immatics.com (IMTX)|Company Future Sales Volume XNCR|CMPX - Company Sales Forecast|Company Future Sales Volume LYEL (Lyell Immunopharma Inc)|Company Projected Revenue Volume IPHA|Projected Sales Volume PYXS (Pyxis Oncology)|Company Future Revenue CGEN|IO Biotech - Projected Sales Volume|Company Expected Sales Volume Sutro Biopharma Inc.|MiNK (INKT) - Company Projected Revenue|Werewolf Therapeutics, Inc. - Company Future Revenue|IMMX (Immix Biopharma Inc.) - Projected Sales Volume|Projected Sales Volume alxoncology.com|Company Projected Revenue Cue Biopharma (CUE)|PDSB: Company Expected Revenue|Sonnet BioTherapeutics Holdings - Company Future Sales Volume|MAIA Bio (MAIA) - Company Expected Sales Volume|LIMN - Company Projected Revenue|Company Future Revenue LVTX (LAVA Therapeutics N.V.)|NXTC: Projected Sales Volume|Company Expected Sales Volume Leap Therapeutics (LPTX)|Company Projected Revenue Intensity Therapeutics Inc|Sensei Bio - Company Expected Revenue|Company Projected Revenue Theriva Biologics, Inc. (TOVX)|Company Projected Revenue GRTS (gritstonebio.com)|Projected Sales Volume KA (Kineta)|Company Future Sales NexImmune Inc (NEXI)|TSBX - Company Projected Revenue|Vaccinex Inc (VCNX) - Company Future Sales Volume|HARP (Harpoon Therapeutics) - Company Future Sales Volume